<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683772</url>
  </required_header>
  <id_info>
    <org_study_id>MA-15-12-15</org_study_id>
    <nct_id>NCT02683772</nct_id>
  </id_info>
  <brief_title>Astral VAPS AutoEPAP Clinical Trial</brief_title>
  <official_title>The Evaluation of the Astral VAPS AutoEPAP Treatment Algorithm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ResMed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic respiratory failure such as those associated with Chronic Obstructive
      Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS), Obstructive Sleep Apnea
      (OSA) or Neuromuscular Disease (NMD) are increasingly managed with domiciliary non-invasive
      positive pressure ventilation (NIPPV). The aim of this study is to now compare the Automatic
      Expiratory Positive Airway Pressure (AutoEPAP) algorithm with a fixed manual EPAP in iVAPS
      mode on an Astral mixed mode ventilator. It is proposed that the automatic settings of
      AutoEPAP will be as effective at managing respiratory failure and upper airway obstruction
      (UAO) as manual EPAP on the Astral device. Specifically demonstrating that the AutoEPAP
      function is as effective at treating UAO as manual EPAP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2016</start_date>
  <completion_date type="Actual">July 6, 2017</completion_date>
  <primary_completion_date type="Actual">March 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients were masked to the mode of treatment. The Core Lab was masked to the mode of treatment for all patients.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygen Desaturation Index 4% (ODI4%)</measure>
    <time_frame>Overnight, up to 8 hrs on nights 1 and 2</time_frame>
    <description>Mean paired difference AutoEPAP-manual EPAP: Comparison of Oxygen Desaturation Index 4% (ODI4%) values between groups by using mean ODI4% (#events/hour). A cross-over analysis was generated to investigate the influence of a possible period effect on the primary endpoint, paired change in ODI4% between Auto and manual EPAP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep Efficiency (%)</measure>
    <time_frame>Overnight, up to 8 hrs on nights 1 and 2</time_frame>
    <description>To assess sleep efficacy between groups by using rapid eye movement sleep (REM) (% of total sleep time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea Hypopnea Index (AHI)</measure>
    <time_frame>Overnight, up 8 hrs on night 1 and 2</time_frame>
    <description>To assess sleep-breathing parameters between groups using mean AHI (#events/hour)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nadir Arterial Oxygen Saturation (SpO2)</measure>
    <time_frame>Overnight, up 8 hrs on night 1 and 2</time_frame>
    <description>To assess Sleep-breathing parameters between groups using mean SpO2 (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Carbon Dioxide (PCO2)</measure>
    <time_frame>Overnight, up 8 hrs on night 1 and 2</time_frame>
    <description>To assess Sleep-breathing parameters between groups using mean PCO2 (mmHg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Upper Airway Obstruction</condition>
  <condition>Respiratory Insufficiency</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>iVAPS with AutoEPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with AutoEPAP on the first night, and on iVAPS with manual EPAP on the second night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iVAPS with manual EPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with manual EPAP on the first night, and on iVAPS with AutoEPAP on the second night.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Astral</intervention_name>
    <description>Astral ventilator</description>
    <arm_group_label>iVAPS with AutoEPAP</arm_group_label>
    <arm_group_label>iVAPS with manual EPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for the study are:

          1. Participant has ability to provide written informed consent

          2. Participants aged ≥18 years old

          3. Participant has documented respiratory failure (e.g. sleep hypoventilation with
             historical PtCO2 increase ≥ 10mmHg) and/or daytime hypercapnia (&gt;45 mmHg)

          4. Participant is currently using non-invasive positive pressure ventilation in ST or
             VAPS mode for ≥ 3 months

          5. Participants with a previously documented AHI ≥ 5/hr

          6. Participants with a recently (≤ 12 months ago) reviewed EPAP setting

        Exclusion criteria for the study are:

          1. Participants are not compliant on NIPPV (e.g. &lt; 4 hr/night)

          2. Participants who are pregnant

          3. Participants on oxygen therapy ≥5 L/min

          4. Participants with an invasive interface (e.g. tracheostomy)

          5. Participants who have had an acute exacerbation within the last 3 months that resulted
             in a hospitalisation

          6. Participants who are acutely ill, medically complicated or who are medically unstable

          7. Participants in whom NIPPV therapy is otherwise medically contraindicated

          8. Participants who have had surgery of the upper airway, nose, sinus, or middle ear
             within the previous 90 days

          9. Participants with untreated, non-OSA sleep disorders, including but not limited to;
             insomnia, periodic limb movement syndrome, or restless legs syndrome.

         10. Participants who have the following pre-existing conditions: severe bullous lung
             disease, recurrent pneumothorax or pneumomediastinum, cerebrospinal fluid leak, recent
             cranial surgery or trauma.

         11. Participant does not comprehend English

         12. Participant is unable or unwilling to provide written informed consent

         13. Participant is physically and/or mentally unable to comply with the protocol

         14. Participant is not suitable to participate in the trial for any other reason in the
             opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Wolfe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lisa F. Wolfe, MD</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Budweiser S, Jörres RA, Riedl T, Heinemann F, Hitzl AP, Windisch W, Pfeifer M. Predictors of survival in COPD patients with chronic hypercapnic respiratory failure receiving noninvasive home ventilation. Chest. 2007 Jun;131(6):1650-8.</citation>
    <PMID>17565016</PMID>
  </reference>
  <reference>
    <citation>Masa JF, Celli BR, Riesco JA, Hernández M, Sánchez De Cos J, Disdier C. The obesity hypoventilation syndrome can be treated with noninvasive mechanical ventilation. Chest. 2001 Apr;119(4):1102-7.</citation>
    <PMID>11296176</PMID>
  </reference>
  <reference>
    <citation>Remmers JE, deGroot WJ, Sauerland EK, Anch AM. Pathogenesis of upper airway occlusion during sleep. J Appl Physiol Respir Environ Exerc Physiol. 1978 Jun;44(6):931-8.</citation>
    <PMID>670014</PMID>
  </reference>
  <reference>
    <citation>Ward S, Chatwin M, Heather S, Simonds AK. Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia. Thorax. 2005 Dec;60(12):1019-24.</citation>
    <PMID>16299118</PMID>
  </reference>
  <reference>
    <citation>Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med. 2003 Jul 1;168(1):10-48. Review.</citation>
    <PMID>12826594</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <results_first_submitted>March 21, 2018</results_first_submitted>
  <results_first_submitted_qc>July 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2019</results_first_posted>
  <disposition_first_submitted>March 7, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 7, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 9, 2018</disposition_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NIV, NIPPV, ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Airway Obstruction</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02683772/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 23, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02683772/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>43 patients consented for this study. One patient did not meet criteria. 42 patients were randomized and began the first study PSG night. 3 patients were found to be ineligible due to I/E criteria not met. Site erroneously placed patient on ST mode for one of the PSG study nights. Thus, there were 38 patients that were analyzed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>iVAPS With AutoEPAP, Then iVAPS With Manual EPAP</title>
          <description>This is a crossover study. After randomization, patients in this arm will receive overnight PSG iVAPS with AutoEPAP first, and the second night iVAPS with manual EPAP. Therapy will be delivered using the clinical trial device, Astral. At least 4 hours of recording will be required.</description>
        </group>
        <group group_id="P2">
          <title>iVAPS With Manual EPAP, Then iVAPS With AutoEPAP</title>
          <description>This is a crossover study. After randomization, patients in this arm will receive overnight PSG iVAPS with manual EPAP first, and the second night iVAPS with AutoEPAP. Therapy will be delivered using the clinical trial device, Astral. At least 4 hours of recording will be required.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is a crossover study. There were 42 patients enrolled in total. 38 patients met the definition of evaluable. These 38 participated in both 'Group A' and 'Group B' intervention assignments. All Baseline characteristics are summarized for these 38 evaluable patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Study Total</title>
          <description>This is a crossover study. There were 42 patients enrolled in total. 38 patients met the definition of evaluable. These 38 participated in both 'Group A' and 'Group B' intervention assignments. All Baseline characteristics are summarized for these 38 evaluable patients.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.33" spread="16.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.41" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Oxygen Desaturation Index 4% (ODI4%)</title>
        <description>Mean paired difference AutoEPAP-manual EPAP: Comparison of Oxygen Desaturation Index 4% (ODI4%) values between groups by using mean ODI4% (#events/hour). A cross-over analysis was generated to investigate the influence of a possible period effect on the primary endpoint, paired change in ODI4% between Auto and manual EPAP</description>
        <time_frame>Overnight, up to 8 hrs on nights 1 and 2</time_frame>
        <population>This is a crossover study. There were 42 patients enrolled in total. 38 patients met the definition of evaluable. These 38 participated in both 'Group A' and 'Group B' intervention assignments. All Baseline characteristics are summarized for these 38 evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>iVAPS With AutoEPAP</title>
            <description>This is a crossover study. There were 42 patients enrolled in total. 38 patients met the definition of evaluable. These 38 participated in both iVAPS with AutoEPAP and iVAPS with manual EPAP intervention assignments. All Baseline characteristics are summarized for these 38 evaluable patients.</description>
          </group>
          <group group_id="O2">
            <title>iVAPS With Manual EPAP</title>
            <description>This is a crossover study. There were 42 patients enrolled in total. 38 patients met the definition of evaluable. These 38 participated in both iVAPS wtih AutoEPAP and iVAPS with manual EPAP intervention assignments. All Baseline characteristics are summarized for these 38 evaluable patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Desaturation Index 4% (ODI4%)</title>
          <description>Mean paired difference AutoEPAP-manual EPAP: Comparison of Oxygen Desaturation Index 4% (ODI4%) values between groups by using mean ODI4% (#events/hour). A cross-over analysis was generated to investigate the influence of a possible period effect on the primary endpoint, paired change in ODI4% between Auto and manual EPAP</description>
          <population>This is a crossover study. There were 42 patients enrolled in total. 38 patients met the definition of evaluable. These 38 participated in both 'Group A' and 'Group B' intervention assignments. All Baseline characteristics are summarized for these 38 evaluable patients.</population>
          <units>events per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="5.67"/>
                    <measurement group_id="O2" value="7.61" spread="18.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The method proposed for this analysis was a one-sided paired t-test using a significance level of 0.05 and a non-inferiority margin of 2 events/hour</non_inferiority_desc>
            <p_value>0.0134</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.45</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>17.23</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Efficiency (%)</title>
        <description>To assess sleep efficacy between groups by using rapid eye movement sleep (REM) (% of total sleep time)</description>
        <time_frame>Overnight, up to 8 hrs on nights 1 and 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>iVAPS With AutoEPAP</title>
            <description>Astral device will be set using iVAPS with autoEPAP for the overnight PSG
Astral: Astral ventilator</description>
          </group>
          <group group_id="O2">
            <title>iVAPS With Manual EPAP</title>
            <description>Astral device will be set using iVAPS with manual EPAP during overnight PSG
Astral: Astral ventilator</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Efficiency (%)</title>
          <description>To assess sleep efficacy between groups by using rapid eye movement sleep (REM) (% of total sleep time)</description>
          <units>percentage of total sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.70" spread="16.41"/>
                    <measurement group_id="O2" value="73.89" spread="19.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apnea Hypopnea Index (AHI)</title>
        <description>To assess sleep-breathing parameters between groups using mean AHI (#events/hour)</description>
        <time_frame>Overnight, up 8 hrs on night 1 and 2</time_frame>
        <population>Analysis population in each arm/group is based on the total number of participants receiving each intervention over two separate nights.</population>
        <group_list>
          <group group_id="O1">
            <title>iVAPS With AutoEPAP</title>
            <description>This is a crossover study. After randomization, patients in this arm will receive overnight PSG iVAPS with AutoEPAP first, and the second night iVAPS with manual EPAP. Therapy will be delivered using the clinical trial device, Astral. At least 4 hours of recording will be required.</description>
          </group>
          <group group_id="O2">
            <title>iVAPS With Manual EPAP</title>
            <description>This is a crossover study. After randomization, patients in this arm will receive overnight PSG iVAPS with manual EPAP first, and the second night iVAPS with AutoEPAP. Therapy will be delivered using the clinical trial device, Astral. At least 4 hours of recording will be required.</description>
          </group>
        </group_list>
        <measure>
          <title>Apnea Hypopnea Index (AHI)</title>
          <description>To assess sleep-breathing parameters between groups using mean AHI (#events/hour)</description>
          <population>Analysis population in each arm/group is based on the total number of participants receiving each intervention over two separate nights.</population>
          <units>events per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" spread="5.55"/>
                    <measurement group_id="O2" value="7.84" spread="15.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nadir Arterial Oxygen Saturation (SpO2)</title>
        <description>To assess Sleep-breathing parameters between groups using mean SpO2 (%)</description>
        <time_frame>Overnight, up 8 hrs on night 1 and 2</time_frame>
        <population>Analysis population in each arm/group is based on the total number of participants receiving each intervention over two separate nights.</population>
        <group_list>
          <group group_id="O1">
            <title>iVAPS With AutoEPAP</title>
            <description>This is a crossover study. After randomization, patients in this arm will receive overnight PSG iVAPS with AutoEPAP first, and the second night iVAPS with manual EPAP. Therapy will be delivered using the clinical trial device, Astral. At least 4 hours of recording will be required.</description>
          </group>
          <group group_id="O2">
            <title>iVAPS With Manual EPAP</title>
            <description>This is a crossover study. After randomization, patients in this arm will receive overnight PSG iVAPS with manual EPAP first, and the second night iVAPS with AutoEPAP. Therapy will be delivered using the clinical trial device, Astral. At least 4 hours of recording will be required.</description>
          </group>
        </group_list>
        <measure>
          <title>Nadir Arterial Oxygen Saturation (SpO2)</title>
          <description>To assess Sleep-breathing parameters between groups using mean SpO2 (%)</description>
          <population>Analysis population in each arm/group is based on the total number of participants receiving each intervention over two separate nights.</population>
          <units>percentage of oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.24" spread="2.36"/>
                    <measurement group_id="O2" value="94.53" spread="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arterial Carbon Dioxide (PCO2)</title>
        <description>To assess Sleep-breathing parameters between groups using mean PCO2 (mmHg)</description>
        <time_frame>Overnight, up 8 hrs on night 1 and 2</time_frame>
        <population>Analysis population in each arm/group is based on the total number of participants receiving each intervention over two separate nights.</population>
        <group_list>
          <group group_id="O1">
            <title>iVAPS With AutoEPAP</title>
            <description>This is a crossover study. After randomization, patients in this arm will receive overnight PSG iVAPS with AutoEPAP first, and the second night iVAPS with manual EPAP. Therapy will be delivered using the clinical trial device, Astral. At least 4 hours of recording will be required.</description>
          </group>
          <group group_id="O2">
            <title>iVAPS With Manual EPAP</title>
            <description>This is a crossover study. After randomization, patients in this arm will receive overnight PSG iVAPS with manual EPAP first, and the second night iVAPS with AutoEPAP. Therapy will be delivered using the clinical trial device, Astral. At least 4 hours of recording will be required.</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Carbon Dioxide (PCO2)</title>
          <description>To assess Sleep-breathing parameters between groups using mean PCO2 (mmHg)</description>
          <population>Analysis population in each arm/group is based on the total number of participants receiving each intervention over two separate nights.</population>
          <units>milimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.49" spread="6.62"/>
                    <measurement group_id="O2" value="45.38" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data were collected for each patient enrolled into the study. AE data was collected from signing of Informed Consent Form until the patient's final completion date (PSG #2).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>iVAPS With AutoEPAP</title>
          <description>This is a crossover study. There were 42 patients randomized in total. 38 patients met the definition of evaluable. These 38 participated in both iVAPS with AutoEPAP and iVAPS with manual EPAP intervention assignments. Adverse Event data were collected for all 42 enrolled patients.</description>
        </group>
        <group group_id="E2">
          <title>iVAPS With Manual EPAP</title>
          <description>This is a crossover study. There were 42 patients randomized in total. 38 patients met the definition of evaluable. These 38 participated in both iVAPS with AutoEPAP and iVAPS with manual EPAP intervention assignments. Adverse Event data were collected for all 42 enrolled patients.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <description>Patient woke up with an asthma exacerbation at 4:37am. Patient utilized her normal home routine treatment. This event was determined to be 'not related' to the device or study treatment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maureen Crocker, Manager Medical Affairs</name_or_title>
      <organization>ResMed</organization>
      <phone>8588366653</phone>
      <email>maureen.crocker@resmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

